×

Celator(R) Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on September 17, 2014

EWING, N.J., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the Celator team, led by Scott Jackson, Chief Executive Officer, will ring the NASDAQ Stock Market Closing Bell this afternoon. The ceremony is in recognition of the company listing on NASDAQ within the past year and to celebrate recent successes, including the development progress made with lead compound, CPX-351, and the decision to broaden potential clinical applications of the Company's proprietary CombiPlex® technology platform.

The event will be broadcast on the major business networks and a live webcast of the NASDAQ Closing Bell can be accessed at http://new.livestream.com/nasdaq/live.

About Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is a pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes lead product, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; a preclinical stage product candidate, CPX-8 (a hydrophobic docetaxel prodrug nanoparticle formulation) being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory; and a program exploring novel combinations of existing drugs, including targeted therapies.

For more information, please visit the company's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.

Forward-Looking Statements:

To the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our research and development programs, the efficacy and commercial potential of our drug candidates, and our performance and achievements to differ significantly from those expressed or implied by the forward-looking statements. Celator undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Celator's Form 10-K for the year ended December 31, 2013 and other filings by the company with the U.S. Securities and Exchange Commission.

CONTACT: Media: Mike Beyer Sam Brown, Inc. 773-463-4211 beyer@sambrown.com Investors: Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 beth@sternir.com

Source:Celator Pharmaceuticals, Inc.